Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,106 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Follow-Up Questions
What is Regeneron Pharmaceuticals Inc (REGN)'s P/E Ratio?
The P/E ratio of Regeneron Pharmaceuticals Inc is 13.4131
Who is the CEO of Regeneron Pharmaceuticals Inc?
Dr. Leonard Schleifer is the Co-Chairman of the Board of Regeneron Pharmaceuticals Inc, joining the firm since 1988.
What is the price performance of REGN stock?
The current price of REGN is $627.69, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Regeneron Pharmaceuticals Inc?
Regeneron Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is Regeneron Pharmaceuticals Inc market cap?
Regeneron Pharmaceuticals Inc's current market cap is $66.5B
Is Regeneron Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 30 analysts have made analyst ratings for Regeneron Pharmaceuticals Inc, including 10 strong buy, 17 buy, 7 hold, 1 sell, and 10 strong sell
